Kornimate/medical-research-clean huggingface dataset:
perceived effectiveness of the vaginal moisturizer investigational product under normal conditions of use.

Conditions: Vaginal Atrophy

Summary: the present research project aims to evaluate the perceived effectiveness of the product under investigation under normal conditions of use for 28 days, to defend the claims "high hydration power, relief of discomfort and improvement of vaginal tone."

this research project aims to evaluate the perceived efficacy of the product under investigation under normal conditions of use for 28 days, to defend the attributes expected for this product category. the study will be carried out through the application of questionnaires, which will be answered by the participants. the study will be conducted with a brazilian sample in which 45 research participants will be included.

Eligibility criteria:
inclusion criteria: 1. age range between 25 and 70 years old. 2. phototypes: i to iv, according to fitzpatrick classification; 3. sex: female 4. intact skin in the evaluation region. 5. participants complaining of vaginal dryness; 6. agree to adhere to the study procedures and requirements: study time, return(s) to the laboratory to perform study procedures, home use of the investigational product, filling out the usage diary, not changing cosmetic habits during the study period . 7. agree not to carry out dermatological or aesthetic treatments until the end of the study and agree not to use any products from the same category as the investigational product. 8. signing of the free and informed consent form (tcle). exclusion criteria: 1. pregnant or breastfeeding women. 2. skin marks in the experimental area that interfere with the assessment of possible skin reactions. 3. active dermatoses (local or disseminated) that could interfere with the study results. 4. history of ineffectiveness, allergic reactions, irritation or intense sensation of discomfort to topical products: health products or medications. 5. expected vaccination during the study or up to 3 weeks before the study; 6. not taking vitamin a (acid and/or its derivatives orally or topically up to 1 month before the start of the study.) 7. patients with immunodeficiencies. 8. history of atopy (atopic dermatitis, allergic rhinitis, allergic bronchitis, allergic conjunctivitis, etc.). 9. use of non-steroidal anti-inflammatory drugs, corticosteroids, antihistamines, photosensitizers or immunosuppressants up to 2 weeks before the study (or considering depot corticosteroids, the interval should be 1 month before the selection). 10. aesthetic or dermatological treatment up to 4 weeks before the study. 11. hormonal treatments not stable in the last 3 months. 12. hyperpigmentation associated with the use of drugs such as tetracyclines, phenothiazides or amiodarone. 13. hyperpigmentation associated with photosensitivity. 14. people directly involved in carrying out this study and their families. 15. history of lack of adherence or unwillingness to adhere to the study protocol. 16. any condition that, in the researcher's opinion, could compromise the study. 17. be participating in another study in the same region of application.
pharmacoeconomic consequences of analgesia in the intensive care unit (icu)

Conditions: Analgesia

Summary: this study will be a multicentre randomized, open-label, phase iiib study. this study will evaluate two different techniques of sedation: an analgesia based regimen with remifentanil versus a conventional sedation based regimen using propofol in subjects that require mechanical ventilation for at least 2 days in the icu. the conventional sedation based regimen will consist of propofol combined with an opioid according to routine clinical practice (morphine, fentanyl, sufentanil or other as required) . the analgesia based regimen will consist of remifentanil, with propofol added on if required.


Eligibility criteria:
inclusion criteria: * medical and post-surgical patients admitted to icu and requiring mechanical ventilation. * intubated subjects expected to require mechanical ventilation for longer than 48 hours after starting the study drug. * subjects requiring both analgesia and sedation with a regimen comprising a hypnotic agent and an opioid. exclusion criteria: * diagnosis: cardiopulmonary resuscitation (cpr) in the previous 24 hours or expecting to require major surgery within the next three days * subject who, in the judgement of the investigator, has a life expectancy of 2 days or refrained or refuses full life support, which would limit the care provided * concurrent medications: * requires or is likely to require neuromuscular blocking agents by continuous infusion to facilitate mechanical ventilation * has or is likely to receive an epidural block during the treatment period

Keywords: analgesia mechanical ventilation pharmaco-economic icu
vest: the uk vedolizumab real life experience study in inflammatory bowel disease

Conditions: Ulcerative Colitis; Crohn's Disease

Summary: vedolizumab has been approved for the treatment of both ulcerative colitis and crohn's disease. the aim of this study is to capture the early real life uk experience of vedolizumab including the outcomes of treatment, describing the patient population treated, drug persistence, ibd control prom, durable remission, tolerance and safety.


Eligibility criteria:
inclusion criteria: * participants being given vedolizumab as part of routine care, and vedo naïve prior to study * age 18 or over * written informed consent obtained from patient for participation in the uk ibd registry exclusion criteria: * patient unwilling to take part in the uk ibd registry * unable to obtain written informed consent * patient is, in the opinion of the investigator, not suitable to participate in the study * patients with contraindications to the use of vedolizumab

Keywords: real world outcomes
plasma rich in growth factors (prgf) treatment for muscle tear

Conditions: Muscle Tear

Summary: the improvement of symptoms and disease progress by the treatment of oa of the knee with prgf


Eligibility criteria:
inclusion criteria: * us diagnosed muscle tear * age 15-40 years old exclusion criteria: * pregnancy * mental or physical disabilities
predicting diabetic retinopathy from risk factor data and digital retinal images

Conditions: Diabetic Retinopathy; Diabetic Macular Edema

Summary: the objective of this study is to compare the results of a deep learning approach to diabetic retinopathy assessment with results from (1) an in-person examination with an ophthalmologist, and (2) the assessments of optometrists involved in a teleretinal screening program.

this study represents the third aim of a grant with five aims. the study will compare and evaluate the predictive accuracy of: (a) machine learning models developed to grade diabetic retinopathy and assess the presence or absence of diabetic macular edema and (b) the assessments of optometrist readers, both from digital retinal images, against standard of care dilated retinal examinations by board-certified ophthalmologists and/or retinal-specialty fellows for 300 diabetic patients utilizing a los angeles county reading center. for the study, the investigators will recruit 300-500 eligible diabetic patients for in-person eye examinations performed by board certified ophthalmologists and/or retinal-specialty fellows at los angeles county reading centers. the study will take place over the course of two visits: a teleretinal screening and an in-person eye examination. the in-person dilated eye examinations that the study participants will participate in and be compensated for follow the usual standard of care that patients receive in a setting that does not utilize teleretinal screening. yearly dilated eye examinations are standard of care for all persons with diabetes.

Eligibility criteria:
inclusion criteria: * patients diagnosed with type i or type ii diabetes * patients who are over the age of 18 years * patients who have not previously been seen in the current year by the lacdhs teleretinal diabetic retinopathy screening program and reading center * patients whose teleretinal screening exam images yield readable results exclusion criteria: * patients under the age of 18 years * patients with gestational diabetes * patients who have previously been seen in the current year by lacdhs's teleretinal diabetic retinopathy screening program and reading center * patients whose teleretinal screening exam images do not yield readable results, as gradable images are needed for later comparison against ophthalmologist reads. * previously eligible patients who do not return for an in-person eye exam within 3 months of receiving a teleretinal screening (in order for the results of the teleretinal screening and in-person eye examinations to yield similar information, patients who do not return for their in-person eye exam within 3 months of their teleretinal screening will not be able to remain in the study. this is because significant eye changes not documented by the teleretinal screening may occur after a 3-month period).
prevalence of temporomandibular joint disorders among egyptian university undergraduate students

Conditions: TMD; Bruxism

Summary: this study will take place in egypt. undergraduate students from different faculties of the egyptian universities will participate. the study began in december 2020.

matching criteria and allocation ratio: the planned study a single arm cross sectional study, in which the prevalence of students of tmd will be reported. the association between tmd and other variables will be also studied. therefore, no matching criteria or allocation ratio are required. variables it has been shown from literature that many variables are associated with tmd. it was therefore, decided to study the correlation between these variables with tmd among egyptian population via a regression model once the assumption for regression analysis are satisfied. binary variables are analyzed through logistic regression, while continuous data through a multivariable regression analysis. if one of the assumptions for regression analysis is violated, a subgroup analysis for each variable will be considered. these variables include gender, age, psychological stress, oral habits, parafunctional activities as gum chewing, previous dental treatments , previous trauma to jaws. data sources and management data sources, the answered questionnaires and subsequent spread sheets will only be shared by the team members. addressing potential sources of bias selection bias: an email will be sent to all the students through their university email addresses. due to the covid-19 situation only convenient sampling could be used. whenever possible printed questionnaires are handed to the students. quantitative variables: handling of quantitative variables in the analyses none of the data is a continuous variable. all exposure factors are binary or categorical data. therefore, no plans are set for simplifying continuous data or converting them into binary ones.

Eligibility criteria:
inclusion criteria: 1. -undergraduate students in egyptian universities 2. age ranges from 18-45 years 3. males and females exclusion criteria 1. school students 2. students not living in egypt
the effectiveness and safety of integrative korean medicine treatment for bell's palsy

Conditions: Facial Paralysis, Peripheral

Summary: this is an observational study that evaluate the effectiveness and safety of korean integrative treatments in patients with peripheral facial nerve palsy. adulthood patients aged between 19 to 69 who were diagnosed with peripheral facial nerve palsy and receive korean integrative treatments for facial palsy will be enrolled in the study and the change will be followed according to the facial disability index (fdi) at the 3 month moment after baseline.

this is an observational study that evaluate the effectiveness and safety of korean integrative treatments in patients with peripheral facial nerve palsy. a total of 100 patients who are in age of from 19 to 69, diagnosed with peripheral facial nerve palsy, in acute to subacute stage, and who receive korean integrative treatments for facial palsy will be enrolled in this study. this study is an observational study and the intervention will be decided not by researchers, but by physicians in the real clinical practice. the treatment will be entirely determined according to each subject's medical conditions by an experienced clinician who has received more than 6 years of education and more than 3 years of training. this study will only record the contents of the intervention. among all the data generated during the study period, data deemed necessary can be collected in the case record forms. the intervention will also be determined by the clinician, and the researcher presented assessment and data collection timepoints, which is independent of the treatment schedule. the on-treatment visit schedule will be once a week during the treatment is ongoing, and follow-up visit schedule will be on the 5th, 14th, and 53rd weeks after the baseline.

Eligibility criteria:
inclusion criteria: 1. age of 19 to 69 2. diagnosed with unilateral peripheral facial nerve palsy 3. onset of facial palsy within 3 weeks or less. 4. an individual who can provide written consent form to participate in the study. exclusion criteria: 1. diagnosed with central nervous system disease causing facial palsy 2. secondary facial palsy after multiple sclerosis, tumor, cerebrovascular disease and temporal bone fracture. 3. ramsay-hunt syndrome 4. bilateral or recurrent facial nerve palsy. 5. an individual who received any treatment that can have a significant effect on changes in facial paralysis within recent 2 month. (ie. facial nerve decompression surgery) 6. already or planned to be pregnant or breast-feeding within the study period. 7. uncontrolled diabetes mellitus within the last 3 months. 8. within a month after participating any other facial palsy-related clinical trials, or planning to participate other clinical trials within 6 month. 9. impossible to read and understand the documents, regarding informed consent form and the questionnaires. 10. difficult to participate according to the judgement of researchers.
post-marketing safety of elasomeran/davesomeran and andusomeran

Conditions: SARS-CoV-2

Summary: the main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.


Eligibility criteria:
inclusion criteria: cohort 1: influenza vaccinated concurrent comparator eligible vaccine episodes must meet the following inclusion criteria within the protocol-specified time windows: * non-missing sex: (start of available data, 1 day prior to index) * no receipt of elasomeran/davesomeran and andusomeran vaccine: (90 days prior to index, 1 day prior to index) * no receipt of influenza vaccine: (90 days prior to index, 1 day prior to index) * no receipt of any other covid-19 vaccine: (90 days prior to index, index date) * continuous enrollment in closed medical and pharmacy claims (365 days prior to index, index date) cohort 2: medically attended covid-19 concurrent comparator eligible vaccine and disease episodes must meet the following inclusion criteria within the specified time windows: * non-missing sex: (start of available data, 1 day prior to index) * no receipt of elasomeran/davesomeran and andusomeran vaccine: (180 days prior to index, 1 day prior to index) * no evidence of medically attended covid-19: (180 days prior to index, 1 day prior to index) * no receipt of any other covid-19 vaccine: (180 days prior to index, index date) * continuous enrollment in closed medical and pharmacy claims (365 days prior to index, index date) exclusion criteria: * vaccine and disease episodes with a prior aesi within the washout window will be excluded from the analytic cohort. * for the influenza vaccinated concurrent comparator cohort, individuals who receive an elasomeran/davesomeran and andusomeran vaccine and an influenza vaccine on the same day or within a minimum number of days will be excluded from the primary analysis. note: other protocol-defined inclusion/exclusion criteria may apply.

Keywords: elasomeran davesomeran andusomeran sars-cov-2 sars-cov-2 vaccine coronavirus virus diseases messenger rna covid-19 covid-19 vaccine moderna
the dose-response relationship of rocuronium in patients taking pyridostigmine

Conditions: Muscle Relaxants

Summary: pyridostigmine is a medication that is used in certain heart rate and blood pressure conditions. this medication, as a side effect, is known to also cause changes in the junction between a nerve and muscle. the changes caused at the nerve muscle junction by pyridostigmine could alter the effect of muscle relaxants (a medication used during surgery and anesthesia). the investigators are conducting this study to see whether patients taking pyridostigmine are more or less sensitive to rocuronium (a muscle relaxing medication used during surgery).

no subjects enrolled. no data collected.

Eligibility criteria:
inclusion criteria: * patients who take pyridostigmine for any reason or those who are matched by age, sex and weight to subjects taking pyridostigmine * patients who will be administered rocuronium during elective procedures as standard clinical care. exclusion criteria: * allergy to rocuronium * known neuromuscular disorder, patients suffering from myasthenia gravis * subjects taking medications known to impact neuromuscular transmission (ex. gentamicin).

Keywords: muscle relaxants pyridostigmine pharmacodynamics potency
inhaled bicarbonate therapy in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to see if inhaled bicarbonate will increase the ability to cough up mucus in a person with cystic fibrosis.

there is evidence that people with cf may have differences in the liquid that lines the surface of their lungs from people without cf. there are two things that are known to be different. one is called bicarbonate secretion, which is the movement of a salt called bicarbonate that is normally present in the blood and lung fluid in all people. the abnormal movement of bicarbonate appears to cause a second abnormality - the liquid in the breathing tubes has more acid than the liquid in patients without cf. these differences may affect the stickiness and thickness of the mucus and limit how well the hairs that line the breathing tubes (cilia) move mucus out of the lungs. recent studies in a group of patients with chronic cough looked at the effects of giving an inhaled bicarbonate solution (sodium bicarbonate instead of sodium chloride) on the study subjects' ability to cough up mucus. compared to the group given inhaled saline, the patients given inhaled bicarbonate were able to cough up approximately three times as much mucus. no clinical studies have looked at whether inhaled bicarbonate improves the ability of the lung in a person with cf to move mucus out of the lung or how this treatment affects lung function in patients with cf.

Eligibility criteria:
inclusion criteria: * age 12 or older * forced expiratory volume in one second (fev1) \>40% predicted * ability to expectorate sputum exclusion criteria: * pregnancy * pulmonary exacerbation or initiation of inhaled or oral antibiotics, steroids, or aerosol treatments within the last four weeks * oxygen saturation \<92%, or requirement for supplemental oxygen

Keywords: cystic fibrosis mucus clearance
determining the risk elevation after maternity

Conditions: Preeclampsia

Summary: evaluating the long term cardiovascular risks of those mothers who have been diagnosed with preeclampsia in pregnancy.

preeclampsia is a complication of pregnancy that happens in about 5-7% of all births. it is diagnosed when a mother has high blood pressure in pregnancy combined with protein in the urine which is sign that the kidneys are not functioning properly. when a mother has preeclampsia, the placenta makes abnormal amounts of several important proteins that damage the lining of the mother's blood vessels. the blood vessel damage that occurs places women at up to 10 times higher risk of having a heart attack or stroke at a younger age than women who did not have preeclampsia. it usually takes between 8 and 15 years after preeclampsia is diagnosed for the first heart attack or stroke to occur. unfortunately, this blood vessel damage is usually silent, meaning that women and their doctors are not aware of it. this makes it hard to predict which women are at highest risk of a heart attack or stroke and therefore need extra medical care to prevent it. abnormal levels of the placenta proteins in the blood (right after delivery and at three and six months after delivery) as well as abnormalities of the placenta itself may be the earliest way to predict which women with preeclampsia are at risk of premature heart disease or stroke. the purpose of this study is to collect blood and placentas from women with preeclampsia and without preeclampsia to measure and compare the levels of proteins in the blood and find abnormalities of the placentas that are associated with preeclampsia. we will then see if these tests can predict which women will go on to develop high blood pressure and ultimately be at higher risk of premature heart attack or stroke after pregnancy.

Eligibility criteria:
inclusion criteria: women with a pregnancy complicated by pre-eclampsia and women who are healthy and have had a normal singleton pregnancy(controls) exclusion criteria: women with any of the following conditions will be excluded in both the control \& preeclampsia groups: 1. known kidney disease prior to pregnancy or laboratory evidence of proteinuria prior to pregnancy 2. diabetes (type i, type ii or gestational diabetes) 3. known cardiovascular disease (myocardial infarction, angina, stroke, or transient ischemic attack 4. multiple pregnancies (twins or more) 5. who do not understand english or french will be excluded in addition to those listed above, for the control group, women must have no other major maternal pregnancy complications.